ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone And Heart Attacks
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 155218" data-attributes="member: 13851"><p><a href="https://www.ecrjournal.com/testosterone-and-heart" target="_blank">Testosterone and the Heart | ECR Journal</a></p><p></p><p></p><p></p><p></p><p></p><p><strong>Abstract</strong></p><p>The development of a subnormal level of testosterone (T) is not universal in ageing men, with 75% of men retaining normal levels. However, a substantial number of men do develop T deficiency (TD), with many of them carrying a portfolio of cardiovascular (CV) risk factors, including type 2 diabetes (T2D) and the metabolic syndrome. TD increases the risk of CV disease (CVD) and the risk of developing T2D and the metabolic syndrome. The key symptoms suggesting low T are sexual in nature, including erectile dysfunction (ED), loss of night-time erections and reduced libido. Many men with heart disease, if asked, admit to ED being present; a problem that is often compounded by drugs used to treat CVD. A large number of studies and meta-analyses have provided evidence of the link between TD and an increase in CVD and total mortality. Patients with chronic heart failure (CHF) who have TD have a poor prognosis and this is associated with more frequent admissions and increased mortality compared with those who do not have TD. Conversely, in men with symptoms and documented TD, T therapy has been shown to have beneficial effects, namely improvement in exercise capacity in patients with CHF, improvement of myocardial ischaemia and coronary artery disease. Reductions in BMI and waist circumference, and improvements in glycaemic control and lipid profiles, are observed in T-deficient men receiving T therapy. These effects might be expected to translate into benefits and there are more than 100 studies showing CV benefit or improved CV risk factors with T therapy. There are flawed retrospective and prescribing data studies that have suggested increased mortality in treated men, which has led to regulatory warnings, and one placebo-controlled study demonstrating an increase in coronary artery non-calcified and total plaque volumes in men treated with T, which is open for debate. Men with ED and TD who fail to respond to phosphodiesterase type 5 (PDE5) inhibitors can be salvaged by treating the TD. There are data to suggest that T and PDE5 inhibitors may act synergistically to reduce CV risk.</p><p></p><p></p><p></p><p></p><p></p><p><strong>Conclusion</strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">The balance of evidence is that T therapy does not increase CV risk. </span></strong><span style="color: rgb(26, 188, 156)"><strong>Many studies have demonstrated that a low serum T concentration is associated with increased CV risk and mortality and that T therapy may have clinically relevant CV benefits.</strong></span></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Evidence demonstrates reduced CV risk with a higher endogenous T concentration, evidence of improvement of known CV risk factors with T therapy and reduced mortality in T deficient men who received T therapy versus untreated men, evidence of improvement of myocardial ischaemia in men with CAD, improved exercise capacity in men with CHF and improvement in serum glucose levels, HbA1c and insulin resistance in men with diabetes and prediabetes.</span></strong></p><p></p><p><span style="color: rgb(26, 188, 156)"><strong>Bearing these facts in mind, when dealing with cardiac patients clinicians need to be alert to the possibility of undisclosed sexual problems and underlying TD, which are amenable to treatment.</strong></span></p><p></p><p><strong>The following statements are the conclusions of the BSSM:1</strong></p><p></p><p></p><ul> <li data-xf-list-type="ul"><span style="color: rgb(44, 130, 201)"><strong>Other benefits of replacing T in deficient men are that beyond 6 months there is evidence of benefit of T therapy in terms of body composition, features of the metabolic syndrome and bone mineralization.</strong></span></li> </ul><p></p><ul> <li data-xf-list-type="ul"><span style="color: rgb(44, 130, 201)"><strong>T therapy also improves sexual desire, erectile function and sexual satisfaction. Reductions in BMI and waist circumference, and improvements in glycaemic control and lipid profiles, are observed in hypogonadal men receiving T therapy.</strong></span></li> </ul><p></p><ul> <li data-xf-list-type="ul"><span style="color: rgb(184, 49, 47)"><strong>Trials of T therapy should extend beyond 6 months and maximal benefit is often seen after 12 months.</strong></span></li> </ul><p></p><ul> <li data-xf-list-type="ul"><span style="color: rgb(44, 130, 201)"><strong>Patients should be informed about the benefits and side-effects of therapy to allow a joint decision regarding the appropriateness of treatment.</strong></span></li> </ul><p></p><ul> <li data-xf-list-type="ul"><span style="color: rgb(44, 130, 201)"><strong>The adverse effects of T therapy should be fully discussed and, where appropriate its potential effect on future fertility for each patient and his partner.</strong></span></li> </ul><p></p><ul> <li data-xf-list-type="ul"><span style="color: rgb(44, 130, 201)"><strong>When T therapy is prescribed, it should be accompanied by weight loss and lifestyle advice as standard management.</strong></span></li> </ul><p></p><p></p><ul> <li data-xf-list-type="ul"><span style="color: rgb(184, 49, 47)"><strong>For patients who are severely symptomatic, with T levels <8 nmol/l, dietary and lifestyle advice alone is unlikely to produce meaningful improvement within a relevant clinical period.</strong></span></li> </ul></blockquote><p></p>
[QUOTE="madman, post: 155218, member: 13851"] [URL='https://www.ecrjournal.com/testosterone-and-heart']Testosterone and the Heart | ECR Journal[/URL] [B]Abstract[/B] The development of a subnormal level of testosterone (T) is not universal in ageing men, with 75% of men retaining normal levels. However, a substantial number of men do develop T deficiency (TD), with many of them carrying a portfolio of cardiovascular (CV) risk factors, including type 2 diabetes (T2D) and the metabolic syndrome. TD increases the risk of CV disease (CVD) and the risk of developing T2D and the metabolic syndrome. The key symptoms suggesting low T are sexual in nature, including erectile dysfunction (ED), loss of night-time erections and reduced libido. Many men with heart disease, if asked, admit to ED being present; a problem that is often compounded by drugs used to treat CVD. A large number of studies and meta-analyses have provided evidence of the link between TD and an increase in CVD and total mortality. Patients with chronic heart failure (CHF) who have TD have a poor prognosis and this is associated with more frequent admissions and increased mortality compared with those who do not have TD. Conversely, in men with symptoms and documented TD, T therapy has been shown to have beneficial effects, namely improvement in exercise capacity in patients with CHF, improvement of myocardial ischaemia and coronary artery disease. Reductions in BMI and waist circumference, and improvements in glycaemic control and lipid profiles, are observed in T-deficient men receiving T therapy. These effects might be expected to translate into benefits and there are more than 100 studies showing CV benefit or improved CV risk factors with T therapy. There are flawed retrospective and prescribing data studies that have suggested increased mortality in treated men, which has led to regulatory warnings, and one placebo-controlled study demonstrating an increase in coronary artery non-calcified and total plaque volumes in men treated with T, which is open for debate. Men with ED and TD who fail to respond to phosphodiesterase type 5 (PDE5) inhibitors can be salvaged by treating the TD. There are data to suggest that T and PDE5 inhibitors may act synergistically to reduce CV risk. [B]Conclusion[/B] [B][COLOR=rgb(184, 49, 47)]The balance of evidence is that T therapy does not increase CV risk. [/COLOR][/B][COLOR=rgb(26, 188, 156)][B]Many studies have demonstrated that a low serum T concentration is associated with increased CV risk and mortality and that T therapy may have clinically relevant CV benefits.[/B][/COLOR] [B][COLOR=rgb(184, 49, 47)]Evidence demonstrates reduced CV risk with a higher endogenous T concentration, evidence of improvement of known CV risk factors with T therapy and reduced mortality in T deficient men who received T therapy versus untreated men, evidence of improvement of myocardial ischaemia in men with CAD, improved exercise capacity in men with CHF and improvement in serum glucose levels, HbA1c and insulin resistance in men with diabetes and prediabetes.[/COLOR][/B] [COLOR=rgb(26, 188, 156)][B]Bearing these facts in mind, when dealing with cardiac patients clinicians need to be alert to the possibility of undisclosed sexual problems and underlying TD, which are amenable to treatment.[/B][/COLOR] [B]The following statements are the conclusions of the BSSM:1[/B] [LIST] [*][COLOR=rgb(44, 130, 201)][B]Other benefits of replacing T in deficient men are that beyond 6 months there is evidence of benefit of T therapy in terms of body composition, features of the metabolic syndrome and bone mineralization.[/B][/COLOR] [/LIST] [LIST] [*][COLOR=rgb(44, 130, 201)][B]T therapy also improves sexual desire, erectile function and sexual satisfaction. Reductions in BMI and waist circumference, and improvements in glycaemic control and lipid profiles, are observed in hypogonadal men receiving T therapy.[/B][/COLOR] [/LIST] [LIST] [*][COLOR=rgb(184, 49, 47)][B]Trials of T therapy should extend beyond 6 months and maximal benefit is often seen after 12 months.[/B][/COLOR] [/LIST] [LIST] [*][COLOR=rgb(44, 130, 201)][B]Patients should be informed about the benefits and side-effects of therapy to allow a joint decision regarding the appropriateness of treatment.[/B][/COLOR] [/LIST] [LIST] [*][COLOR=rgb(44, 130, 201)][B]The adverse effects of T therapy should be fully discussed and, where appropriate its potential effect on future fertility for each patient and his partner.[/B][/COLOR] [/LIST] [LIST] [*][COLOR=rgb(44, 130, 201)][B]When T therapy is prescribed, it should be accompanied by weight loss and lifestyle advice as standard management.[/B][/COLOR] [/LIST] [LIST] [*][COLOR=rgb(184, 49, 47)][B]For patients who are severely symptomatic, with T levels <8 nmol/l, dietary and lifestyle advice alone is unlikely to produce meaningful improvement within a relevant clinical period.[/B][/COLOR] [/LIST] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone And Heart Attacks
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top